Aroa Biosurgery Ltd. engages in the development, manufacturing, and marketing of soft tissue repair products. The company develops, manufactures, sells, and distributes medical and surgical products to improve healing in complex wounds and soft tissue reconstruction. Its products are developed from the AROA extracellular matrix (ECM) technology platform, an extracellular matrix biomaterial derived from the ovine forestomach. AROA ECM is an ECM biomaterial containing a rich and complex mix of biological molecules that serve as the building blocks for a range of soft tissue repair products. Its products include Endoform, Myriad Matrix, Myriad Morcells, Myriad Morcells Fine, Symphony, and Reinforced Bioscaffolds. Endoform products support all phases of wound healing and are appropriate for use early in wound management to restore protease balance and advance healing to the proliferative phase. Myriad Matrix is an engineered ECM designed for soft tissue repair, reinforcement, and complex wounds.
AROAF'ün son EPS'si beklentilerle karşılaştırıldığında nasıldı?
Aroa Biosurgery Ltd'in en son EPS'si $ olup, $ beklentilerini .
Aroa Biosurgery Ltd AROAF'ün son çeyrekteki geliri nasıl performans gösterdi?
Aroa Biosurgery Ltd'in son çeyrek geliri $
Aroa Biosurgery Ltd'in gelir tahmini nedir?
Wall Street analistine göre, Aroa Biosurgery Ltd'in gelir tahmini $ ile $ arasında değişmektedir.
Aroa Biosurgery Ltd'in kazanç kalite puanı nedir?
Aroa Biosurgery Ltd'in kazanç kalite puanı /'dir. Puan, karlılık, büyüme, nakit üretimi ve sermaye tahsisi ile kaldıraç olmak üzere dört boyuta dayanır.
Aroa Biosurgery Ltd kazançlarını ne zaman rapor eder?
Aroa Biosurgery Ltd'in bir sonraki kazanç raporu 2026-02-22'te bekleniyor